Certain universal neoepitopes and cancer specific neoepitopes and methods therefor are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.

The present application relates to novel therapeutic agents, particularly to agents capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling, wherein said agents do not activate Frizzled/LRP -mediated Wnt signaling in the absence of RECK and/or GPR124. The present agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders comprising neurovascular dysfunction.

The present invention relates to the provision of a recombinant AIM that maintains functions, does not multimerize, and is not inactivated by IgM (e.g., a protein containing an amino acid sequence wherein cysteine at amino acid number 168 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, and the like).

The present disclosure relates to methods for producing proteins, cells for producing proteins, and methods for producing cells with improved protein production. In certain embodiments, the present disclosure provides a method of producing a selected protein, the method comprising expressing the selected protein in a cell expressing a Rheb (Ras homologue enriched in brain) protein having an activity to increase protein production in the cell, and secreting the selected protein from the cell, thereby producing the protein.

The present invention relates to an immune cell that are engineered to overexpress cell signaling pathway modulator(s) and a use thereof. As a specific example, an immune cell expressing a fusion protein comprising a chimeric antigen receptor and a cell signaling pathway modulator(s) performs an immune response by selecting a target cancer cell by a chimeric antigen receptor expressed on a cell membrane. In this case, the cell signaling pathway modulator is overexpressed in the cytoplasm, thereby being capable of regulating the activity of an immune cell. Therefore, the fusion protein comprising a chimeric antigen receptor and cell signaling pathway modulator(s), and the immune cell engineered to overexpress the cell signaling pathway modulator(s) of the present invention can be usefully used in the treatment of cancer.

Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels.

Provided herein are compositions and methods for the design of synthetic regulatory sequences and for subsequent modulation of neural pathways.

The present disclosure relates to an advanced in vivo reprogramming system and a cell conversion method using same. The reprogramming system of the present disclosure comprises a start cell marker promoter, a pluripotency-maintaining gene protein, an amino acid isolation peptide, Cre recombinase, a target cell marker promoter, LoxP, and a gene encoding a fluorescent protein, does not require cell fixation in order to confirm cell conversion, enables real-time monitoring in a living cell state, and may be used both in vitro and in vivo. Therefore, the present disclosure is expected to be widely used in the biological and medical fields.

The present disclosure is directed to method of generating human glomeruli endothelial cells (HGECs) from human endothelial cells (ECs), comprising expressing in human ECs an exogenous nucleic acid encoding a T-box transcription factor 3 (Tbx3), alone or in combination with one or more of PR domain zinc finger protein 1 (Prdm1), GATA Binding Protein 5 (Gata5) and Pre-B-Cell Leukemia Transcription Factor 1 (Pbx1). Disclosed also are HGECs produced by the methods of the instant disclosure, as well as methods for using the same.

Disclosed is an auto-induction regulatory system based on quorum sensing, comprising luxI, luxR and egfp, wherein, the promoter for controlling the expression of luxI and luxR is selected from P.sub.luxI, P.sub.BB or P.sub.J23100; the promoter for controlling the expression of egfp is selected from P.sub.luxI, P.sub.luxI(T-38C) or P.sub.luxI(C-77T). Also disclosed are an application of the auto-induction regulatory system based on quorum sensing in the automatic regulation of expression of a target gene of engineered Escherichia coli, as well as an application thereof in the preparation of alginate lyase and esterase. Further disclosed are a recombinant expression vector and a recombinant engineered bacterium comprising the auto-induction regulatory system based on quorum sensing.